about 3 years ago

South Korea suspends AstraZeneca COVID-19 shots for people under 60 amid European review

South Korea said on เล่นเกมสล็อตฟรี it will temporarily suspend providing AstraZeneca's COVID-19 vaccine to people below 60 amid a European review, while approving a Johnson & Johnson shot in a bid to speed up its inoculation roll-out.

The European Medical Agency (EMA) is due to announce the results of a review on whether some cases of blood clotting in adults may be linked to the AstraZeneca shot.

The announcement is due at 2pm GMT (10pm, Singapore time).

Global controversy over the efficacy and side-effects of some COVID-19 vaccines has caused some delays in South Korea's vaccination campaign, which kicked off in late February with the goal of reaching herd immunity in November.

AstraZeneca has said previously its studies have found no higher risk of clots because of its vaccine, millions of doses of which have been administered worldwide. The World Health Organization and EMA have both said the benefits outweigh the risks.

South Korea's food and drug safety ministry said on Wednesday it had granted final approval for Johnson & Johnson's (J&J) vaccine after a panel of experts ruled the single-dose shot was safe and effective.

J&J is the third COVID-19 vaccine maker to be authorised in South Korea, after AstraZeneca and Pfizer-BioNTech, both of which require two doses.

Authorities are seeking to speed up a national vaccination campaign despite global supply shortages, while expanding preemptive testing and tracing efforts amid concerns over a potential fourth wave of infections.

The Korea Disease Control and Prevention Agency (KDCA) reported 668 new cases for Tuesday, the highest level since Jan 8, with clusters developing in kindergartens, saunas, bars and churches, mostly in the greater Seoul area.

To date, total infections stand at 106,898, with 1,756 deaths.